文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Spautin-1通过诱导线粒体损伤介导的PANoptosis和抗肿瘤免疫来抑制弥漫性大B细胞淋巴瘤的生长。

Spautin-1 inhibits the growth of diffuse large B-cell lymphoma by inducing mitochondrial damage-mediated PANoptosis and anti-tumor immunity.

作者信息

Wu Jingjing, Deng Yuan, Gao Yong, Wei Bin

机构信息

Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.

Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.

出版信息

Cancer Immunol Immunother. 2025 Aug 25;74(9):293. doi: 10.1007/s00262-025-04150-9.

DOI:10.1007/s00262-025-04150-9
PMID:40853486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12378856/
Abstract

The prognosis of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Therefore, searching for new therapeutic agents is particularly important to improve therapeutic efficacy. Targeting the ubiquitin-proteasome system is a potential therapeutic strategy for treating DLBCL. In this study, we investigated the role of the deubiquitase inhibitor Spautin-1 in the treatment of DLBCL. Spautin-1 significantly inhibited the growth of DLBCL, including the growth of cells and transplanted tumors in mice. Notably, Spautin-1 showed enhanced tumor suppression in immune-competent versus immunodeficient mice models, mediated by CD8 T cell infiltration and activation. Mechanistically, Spautin-1 promotes PANoptosis by inducing mitochondrial damage mediated by USP13-ACLY inhibition in DLBCL cells, which in turn induces the release of injury-related molecular patterns and cytokines. Moreover, high USP13 expression in DLBCL is associated with poor prognosis and blocks CD8 T cell infiltration. In summary, Spautin-1 may inhibit the growth of DLBCL cells by promoting mitochondrial damage-mediated PANoptosis and anti-tumor immunity, providing a potential strategy for DLBCL therapy.

摘要

复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）的预后较差。因此，寻找新的治疗药物对于提高治疗效果尤为重要。靶向泛素-蛋白酶体系统是治疗DLBCL的一种潜在治疗策略。在本研究中，我们研究了去泛素化酶抑制剂Spautin-1在DLBCL治疗中的作用。Spautin-1显著抑制了DLBCL的生长，包括细胞生长和小鼠体内移植瘤的生长。值得注意的是，在免疫健全与免疫缺陷小鼠模型中，Spautin-1通过CD8 T细胞浸润和激活表现出更强的肿瘤抑制作用。机制上，Spautin-1通过诱导DLBCL细胞中USP13-ACLY抑制介导的线粒体损伤来促进PAN凋亡，进而诱导损伤相关分子模式和细胞因子的释放。此外，DLBCL中USP13的高表达与预后不良相关，并阻碍CD8 T细胞浸润。总之，Spautin-1可能通过促进线粒体损伤介导的PAN凋亡和抗肿瘤免疫来抑制DLBCL细胞的生长，为DLBCL治疗提供了一种潜在策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/b95209300de4/262_2025_4150_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/e544a6776930/262_2025_4150_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/23165b1d7963/262_2025_4150_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/5ce4233e026e/262_2025_4150_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/b699a5db9aad/262_2025_4150_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/866dbcda94f5/262_2025_4150_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/ea5c1460a5c6/262_2025_4150_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/b95209300de4/262_2025_4150_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/e544a6776930/262_2025_4150_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/23165b1d7963/262_2025_4150_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/5ce4233e026e/262_2025_4150_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/b699a5db9aad/262_2025_4150_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/866dbcda94f5/262_2025_4150_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/ea5c1460a5c6/262_2025_4150_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bd2/12378856/b95209300de4/262_2025_4150_Fig7_HTML.jpg

相似文献

[1]
Spautin-1 inhibits the growth of diffuse large B-cell lymphoma by inducing mitochondrial damage-mediated PANoptosis and anti-tumor immunity.

Cancer Immunol Immunother. 2025-8-25

[2]
Damnacanthus giganteus extract block diffuse large b-cell lymphoma proliferation and EMT by regulating mitochondrial dysfunction and glycolysis.

Hereditas. 2025-8-25

[3]
Response gene to complement 32 promotes tumorigenesis by mediating DNA damage repair and inhibits CD8+ T cells infiltration in diffuse large B-cell lymphoma.

Front Immunol. 2025-7-16

[4]
Macrophage Membrane-Coated Liposomes Delivering Vonoprazan Disrupt Mitochondrial Oxidative Phosphorylation in Diffuse Large B-Cell Lymphoma.

Int J Nanomedicine. 2025-6-24

[5]
Magnolin Promotes PINK1-Parkin-mediated Mitophagy in Diffuse Large B-cell Lymphoma Cells via PPAR-γ Pathway.

Phytomedicine. 2025-7-7

[6]
FDX1 promotes elesclomol-induced PANoptosis in diffuse large B-cell lymphoma via activating IRF3/IFN-β signaling.

Oncogene. 2025-4-16

[7]
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma.

Invest New Drugs. 2025-5-1

[8]
ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-Ca-Calcineurin-NFAT-IFN-γ pathway.

Sci Rep. 2025-8-21

[9]
DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.

Apoptosis. 2024-10

[10]
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Cochrane Database Syst Rev. 2021-9-13

本文引用的文献

[1]
Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.

Biomolecules. 2025-2-7

[2]
PANoptosis: A new era for anti-cancer strategies.

Life Sci. 2024-12-15

[3]
Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope.

Mol Cancer. 2024-11-15

[4]
Morusin, a novel inhibitor of ACLY, induces mitochondrial apoptosis in hepatocellular carcinoma cells through ROS-mediated mitophagy.

Biomed Pharmacother. 2024-11

[5]
Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3β-ULK1 axis.

Cell Biosci. 2024-9-2

[6]
Mitochondrial dysfunction: mechanisms and advances in therapy.

Signal Transduct Target Ther. 2024-5-15

[7]
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2024

[8]
NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update.

Nucleic Acids Res. 2024-1-5

[9]
PANoptosis: Mechanisms, biology, and role in disease.

Immunol Rev. 2024-1

[10]
Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application.

J Exp Clin Cancer Res. 2023-9-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索